The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: A cohort study

Annals of Internal Medicine

Volumn 151, Issue 2, 2009, Pages 73-84

  Palella Jr , Frank J ^a   Armon, Carl ^b   Buchacz, Kate ^c   Cole, Stephen R ^d   Chmiel, Joan S ^a   Novak, Richard M ^b   Wood, Kathleen ^e   Moorman, Anne C ^c   Brooks, John T ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Centers for Disease Control and Prevention ^*  (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d IL   (United States)

^e CERNER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; GENOTYPE PHENOTYPE CORRELATION; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SURVIVAL; TREATMENT DURATION; VIRUS LOAD;

EID: 67651089497     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-151-2-200907210-00003     Document Type: Article

References (27)

1. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al; International AIDS Society-USA panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-43. [PMID: 16905788]
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services; 2008. Accessed at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf on 18 May 2009.
3. Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113-28. [PMID: 12830416]
4. EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. AIDS. 2001;15:309-20. [PMID: 11273210]
5. AIDS Education Training Centers. Clinical Manual for the Management of the HIV-Infected Adult. 2006 ed. Newark, NJ: AIDS Education Training Centers National Resource Center; 2006. Accessed at www.aidsetc.org/aetc/pdf/AETC-CM-092206.pdf on 18 May 2009.
6. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14:F83-93. [PMID: 10894268]
7. Wensing AM, van de Vijver DA, Angarano G, AsjöB, Balotta C, Boeri E, et al; SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-66. [PMID: 16107947]
8. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002;15:247-77. [PMID: 11932232]
9. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, et al. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440-50. [PMID: 11255519]
10. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393-401. [PMID: 15199315]
11. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94. [PMID: 12167680]
12. Brown AJ, Precious HM, Whitcomb JM, Wong JK, Quigg M, Huang W, et al. Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol. 2000;74: 10269-73. [PMID: 11044070]
13. Little SJ. Is transmitted drug resistance in HIV on the rise? It seems so [Editorial]. BMJ. 2001;322:1074-5. [PMID: 11337420]
14. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM Jr, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174-80. [PMID: 15181563]
15. Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada. HIV-1 Strain and Primary Drug Resistance in Canada: Surveillance Report to March 31, 2005. Ottawa, Ontario, Canada: Public Health Agency of Canada; 2005. Accessed at www.phac-aspc.gc.ca/publicat/hiv1-vih1-05/index.html on 18 May 2009.
16. Moorman AC, Holmberg SD, Marlowe SI, Von Bargen JC, Yangco BG, Palella FJ, et al. Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS). Ann Epidemiol. 1999;9:349-57. [PMID: 10475534]
17. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-70. [PMID: 10955409]
18. Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158:687-94. [PMID: 14507605]
19. Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Dyke RB, et al; Pediatric AIDS Clinical Trials Group 219/219C Study Team. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis. 2008;46:1751-60. [PMID: 18426371]
20. Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3:e356. [PMID: 16984218]
21. Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS. 2004;18:1539-48. [PMID: 15238772]
22. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother. 2005;55: 413-6. [PMID: 15722389]
23. Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol. 2002;76:11104-12. [PMID: 12368352]
24. Martinez-Picado J, Wrin T, Frost SD, Clotet B, Ruiz L, Brown AJ, et al. Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1. J Virol. 2005;79:5907-13. [PMID: 15857976]
25. Sarmati L, Nicastri E, Parisi SG, d'Ettorre G, Mancino G, Narciso P, et al. Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells. J Clin Microbiol. 2002;40:335-40. [PMID: 11825939]
26. Beerenwinkel N, Däumer M, Oette M, Korn K, Hoffmann D, Kaiser R, et al. Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res. 2003;31:3850-5. [PMID: 12824435]
27. Hales G, Birch C, Crowe S, Workman C, Hoy JF, Law MG, et al; CREST Investigators. A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study. PLoS Clin Trials. 2006; 1:e18. [PMID: 16878178]